Long-term results of NOPHO ALL-92 and ALL-2000 studies of childhood acute lymphoblastic leukemia. - Wikidata - wikimedia - TriplyDB

Long-term results of NOPHO ALL-92 and ALL-2000 studies of childhood acute lymphoblastic leukemia.

Long-term results of NOPHO ALL-92 and ALL-2000 studies of childhood acute lymphoblastic leukemia.

http://www.wikidata.org/entity/Q43221788

about

Clinical Pharmacogenetics Implementation Consortium guidelines for thiopurine methyltransferase genotype and thiopurine dosing Can knowledge of germline markers of toxicity optimize dosing and efficacy of cancer therapy?A health-care system perspective on implementing genomic medicine: pediatric acute lymphoblastic leukemia as a paradigm Mercaptopurine/Methotrexate maintenance therapy of childhood acute lymphoblastic leukemia: clinical facts and fiction Childhood Acute Lymphoblastic Leukemia: Progress Through Collaboration Outcome of central nervous system relapses in childhood acute lymphoblastic leukaemia--prospective open cohort analyses of the ALLR3 trial Incidence and survival rates of hematological malignancies in Japanese children and adolescents (2006-2010): based on registry data from the Japanese Society of Pediatric Hematology.Genomic profiling of thousands of candidate polymorphisms predicts risk of relapse in 778 Danish and German childhood acute lymphoblastic leukemia patients.Mercaptopurine metabolite levels are predictors of bone marrow toxicity following high-dose methotrexate therapy of childhood acute lymphoblastic leukaemia.Genome-wide signatures of differential DNA methylation in pediatric acute lymphoblastic leukemia.Host thiopurine methyltransferase status affects mercaptopurine antileukemic effectiveness in a murine model Clinical and genetic features of pediatric acute lymphoblastic leukemia in Down syndrome in the Nordic countries.Thiopurine S-methyltransferase polymorphisms in acute lymphoblastic leukemia, inflammatory bowel disease and autoimmune disorders: influence on treatment response Bioinformatic description of immunotherapy targets for pediatric T-cell leukemia and the impact of normal gene sets used for comparison.Childhood B-acute lymphoblastic leukemia: a genetic update.Dose intensification of methotrexate and cytarabine during intensified continuation chemotherapy for high-risk B-precursor acute lymphoblastic leukemia: POG 9406: a report from the Children's Oncology Group.Establishment of an 11-year cohort of 8733 pediatric patients hospitalized at United States free-standing children's hospitals with de novo acute lymphoblastic leukemia from health care administrative data.DNA methylation analysis of bone marrow cells at diagnosis of acute lymphoblastic leukemia and at remission.Genetic landscape of high hyperdiploid childhood acute lymphoblastic leukemia.Inherited coding variants at the CDKN2A locus influence susceptibility to acute lymphoblastic leukaemia in children.Clinical outcome of children with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia treated between 1995 and 2005.Improved prognosis for older adolescents with acute lymphoblastic leukemia.Postrelapse survival in childhood acute lymphoblastic leukemia is independent of initial treatment intensity: a report from the Children's Oncology Group.Biology, risk stratification, and therapy of pediatric acute leukemias: an update.Promoter DNA methylation pattern identifies prognostic subgroups in childhood T-cell acute lymphoblastic leukemia The mutational landscape in pediatric acute lymphoblastic leukemia deciphered by whole genome sequencing.Epidemiology of therapy-related myeloid neoplasms after treatment for pediatric acute lymphoblastic leukemia in the nordic countries.Accurate detection of subclonal single nucleotide variants in whole genome amplified and pooled cancer samples using HaloPlex target enrichment.Escalating intravenous methotrexate improves event-free survival in children with standard-risk acute lymphoblastic leukemia: a report from the Children's Oncology Group.DNA methylation-based subtype prediction for pediatric acute lymphoblastic leukemia.Drug metabolizing enzyme activities versus genetic variances for drug of clinical pharmacogenomic relevance.Deep sequencing and SNP array analyses of pediatric T-cell acute lymphoblastic leukemia reveal NOTCH1 mutations in minor subclones and a high incidence of uniparental isodisomies affecting CDKN2A Methotrexate resistance in relation to treatment outcome in childhood acute lymphoblastic leukemia.Prognostic significance of minimal residual disease in high risk B-ALL: a report from Children's Oncology Group study AALL0232.Outcomes after induction failure in childhood acute lymphoblastic leukemia.Pediatric acute lymphoblastic leukemia: where are we going and how do we get there?Epigenetic landscape correlates with genetic subtype but does not predict outcome in childhood acute lymphoblastic leukemia Relapsed childhood acute lymphoblastic leukemia in the Nordic countries: prognostic factors, treatment and outcome.Genetic risk factors for the development of osteonecrosis in children under age 10 treated for acute lymphoblastic leukemia.Polymorphisms in the ABCB1 gene and effect on outcome and toxicity in childhood acute lymphoblastic leukemia

P2860

Q24632749-BEF18602-CEBB-4B07-BFE7-834CD00AE2D5 Q26859144-403F4D42-52DB-403C-8386-AD9D1DFF82F0 Q26866379-B6F6338A-BC7F-4A0B-96A7-DF02FDF77294 Q27023839-5CA2C237-166A-4655-B888-A9D5C1B119AF Q28087637-7C728C5B-3B98-4DAE-9155-EBCBBD2C5ABB Q28543517-92134319-FD10-42B5-8D1D-AC2DC58BDBC8 Q30631947-60AF3906-EECD-4D12-A10A-FFDA50A8769E Q31170949-4189D899-91C6-4AA1-B7AF-39541F53E873 Q33421300-C01BFE5B-4724-4ABF-BA4F-F7F87C208506 Q33585130-E7A6CD59-BE8C-4B79-9CD8-49AA87E97F4B Q33603164-0F0332DB-E326-4BCE-AFB9-42AC878DAFDE Q33615910-332DA28A-69F1-4046-B6FF-62816F4AB023 Q33674158-63674241-293F-49EA-8349-ECBCA5019167 Q33729728-FF0BE341-2FA0-42C6-876A-11C5DF3085D2 Q33777616-E98CEB0F-BDD4-4E25-8F57-888D83EA8468 Q33998291-F0DC52A6-0986-4F14-99AB-F190973A6B0A Q34192080-AEA74940-08A3-43F0-A437-2A1E0C76F90B Q34228412-4B81AF4B-F030-4AE2-971F-889EC3B90E0E Q34411660-D767AA57-15E0-41EB-9FC7-EDD834A8FE28 Q34482019-E67B99E4-9F93-48A2-92A2-A69FC29FA65C Q34488796-A79A6BA0-BD8A-4AA1-8B6A-083A14CBE747 Q34679298-26A18177-9A14-4D40-9169-AD842BEE4874 Q34707213-409973FD-8977-4676-B5C2-10C510EF34DB Q34764504-42EE1D9E-C695-4D01-8CB8-605C35FE2EF9 Q34769855-AABD4231-DB5C-49BD-B7D3-7CF41F61FF22 Q35023231-0CB7304A-1E23-43A2-8769-6991EDADA9C5 Q35040001-88E5A498-1D33-4D29-84F1-B7A9848C3F81 Q35061962-0A582948-B7BC-46A4-8342-C7E519F84731 Q35112206-777C7FA1-34C7-4F9F-9CD3-0B01658DAE1C Q35129383-DDF88E7A-A5A9-44EA-9B4A-2CA67D509B88 Q35206306-EDE2B295-8361-4202-A2AE-FB8F910941EC Q35545539-8439BBB8-FFFC-4E29-A4C6-992A412D5429 Q35684384-D5EA017D-4DF0-4899-81ED-43717C48BF07 Q35976588-762B068F-7757-461E-8F9C-3C8546921F9A Q36029619-AA50B128-4F3B-4C95-A67A-000AE25EA625 Q36163029-8A6D909E-FC68-4CF5-BC72-0FF319925DC3 Q36213239-C9C979DB-DBA2-4F06-9EAF-53DEABA16AD8 Q36420748-7A8142AF-6583-4939-B8C9-19B93BDA13A1 Q36547791-1529B433-DC10-4CEC-87AE-6892B9781C58 Q36605135-65E38A8C-AAB2-4E86-9608-BDB903AA2FDF

P2860

Long-term results of NOPHO ALL-92 and ALL-2000 studies of childhood acute lymphoblastic leukemia.

http://www.wikidata.org/entity/Q43221788

description

2009 nî lūn-bûn

@nan

2009年の論文

@ja

2009年学术文章

@wuu

2009年学术文章

@zh

2009年学术文章

@zh-cn

2009年学术文章

@zh-hans

2009年学术文章

@zh-my

2009年学术文章

@zh-sg

2009年學術文章

@yue

2009年學術文章

@zh-hant

name

Long-term results of NOPHO ALL ...... acute lymphoblastic leukemia.

@en

Long-term results of NOPHO ALL ...... acute lymphoblastic leukemia.

@nl

type

label

Long-term results of NOPHO ALL ...... acute lymphoblastic leukemia.

@en

Long-term results of NOPHO ALL ...... acute lymphoblastic leukemia.

@nl

prefLabel

Long-term results of NOPHO ALL ...... acute lymphoblastic leukemia.

@en

Long-term results of NOPHO ALL ...... acute lymphoblastic leukemia.

@nl

P1433

Q43221788-73E6DDE0-B6AD-43DF-BCD8-24F7405D86C0

P1476

Q43221788-BE19500C-45CA-4B90-8834-041711EBC031

P2093

Q43221788-079F1734-80D9-47C0-92D5-EEAFCF6FC0CC

Q43221788-13B8D166-9540-47C9-88BC-DFF4CBCD20A7

Q43221788-28B03B4B-F7D5-4839-8B3F-FF5A24611EF1

Q43221788-2A9CC709-5CD8-4FD4-A0B1-829207506FA5

Q43221788-95ADD82B-CB57-4C41-A64B-5F62C1885780

Q43221788-EBCEF709-7205-4C4D-B735-7A3E8F8F4479

Q43221788-F08879CC-06CE-4D5D-A989-77169903E733

P2860

Q43221788-283EE1CB-E8D7-481D-A8F0-0C8910D0320A

Q43221788-39755F13-F4A2-4E2A-B606-9A210BB4A818

Q43221788-3D75F4F4-A474-49D0-B0A6-6739AB29293B

Q43221788-4F5BABFD-2A9C-4CDB-9663-983797602318

Q43221788-532BE1FF-2891-478B-9E9C-6747B4A4C637

Q43221788-5D4F61A3-4082-458E-B9F5-09DCBE4D0F5C

Q43221788-646EB45E-FF44-4E3A-986F-696BF6C75937

Q43221788-6542F5FF-CA87-4195-A64A-56C25EA83D69

Q43221788-6EB4FFE9-A8A8-4ADD-BBEB-C3BEE192DD38

Q43221788-6F00AC80-59FF-4E7E-859B-A4B7DAE51481

P2888

Q43221788-6386E7C0-4D49-41A3-92D7-8F8A9F863881

P304

Q43221788-B8C6A641-B808-4C39-9AB4-C71AE8CEADC2

P31

Q43221788-75E9658A-4FEE-4A84-A3A9-EE10E89667E3

P356

Q43221788-6DDCEE23-F0F4-473A-91DF-155C1EBD669E

P433

Q43221788-715DC2A1-6BE7-4BBA-B6E0-4440526B84C9

P478

Q43221788-D92CF967-5974-4D61-86FD-E764389C6BAC

P50

Q43221788-B46A1E6F-8D84-49A3-9D01-55BE3D846D4D

P577

Q43221788-3D62DEE2-CA1A-49A2-970F-1C2D2F11DC71

P6179

Q43221788-90C045FC-49C6-4FDA-BD73-1020F3DEB422

P698

Q43221788-829E9D43-163B-4CE1-B505-D15C0110AF58

P921

Q43221788-1FD35BAB-4848-4E04-85ED-97FC9C65A12B

P356

P1433

P1476

Long-term results of NOPHO ALL ...... acute lymphoblastic leukemia.

@en

P2093

E Forestier

http://www.w3.org/2001/XMLSchema#string

J Kristinsson

http://www.w3.org/2001/XMLSchema#string

M Hellebostad

http://www.w3.org/2001/XMLSchema#string

M Heyman

http://www.w3.org/2001/XMLSchema#string

M Taskinen

http://www.w3.org/2001/XMLSchema#string

Nordic Society of Paediatric Haematology and Oncology

http://www.w3.org/2001/XMLSchema#string

S Söderhäll

http://www.w3.org/2001/XMLSchema#string

P2860

Genome-wide analysis of genetic alterations in acute lymphoblastic leukaemia

Outcome of treatment in children with hypodiploid acute lymphoblastic leukemia.

Clinical and cytogenetic features of pediatric dic(9;20)(p13.2;q11.2)-positive B-cell precursor acute lymphoblastic leukemias: a Nordic series of 24 cases and review of the literature.

Allogeneic transplantation for childhood ALL.

Minimal residual disease in acute lymphoblastic leukemia

Current management and challenges of malignant disease in the CNS in paediatric leukaemia.

Methotrexate/6-mercaptopurine maintenance therapy influences the risk of a second malignant neoplasm after childhood acute lymphoblastic leukemia: results from the NOPHO ALL-92 study

Pharmacogenetics influence treatment efficacy in childhood acute lymphoblastic leukemia.

Thiopurine methyltransferase activity is related to the risk of relapse of childhood acute lymphoblastic leukemia: results from the NOPHO ALL-92 study.

Feasibility and toxicity of intrathecal liposomal cytarabine in 5 children and young adults with refractory neoplastic meningitis.

P2888

P304

345-354

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/LEU.2009.251

http://www.w3.org/2001/XMLSchema#string

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

24

http://www.w3.org/2001/XMLSchema#string

P50

Kjeld Schmiegelow

P577

2009-12-10T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1034618149

http://www.w3.org/2001/XMLSchema#string

P698

20010622

http://www.w3.org/2001/XMLSchema#string

P921